5-溴-1-苯并呋喃-2-甲醛 | 23145-16-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 5-溴-1-苯并呋喃-2-甲醛
• 英文名称: 5-bromo-1-benzofuran-2-carbaldehyde
• CAS: 23145-16-6
• 化学式: C₉H₅BrO₂
• mdl: MFCD06659072
• 分子量: 225.041
• InChiKey: UPEGFMDITWHVHV-UHFFFAOYSA-N

物化性质

• 熔点：
  129 °C
• 沸点：
  312.4±22.0 °C(Predicted)
• 密度：
  1.676±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2932999099
• 安全说明：
  S22,S26,S36/37/39
• 储存条件：
  储存条件：2-8°C，避光保存，需在惰性气体氛围下存放。

SDS

Name:	5-Bromobenzo[b]furan-2-carbaldehyde Material Safety Data Sheet
Synonym:
CAS:	23145-16-6

Section 1 - Chemical Product MSDS Name:5-Bromobenzo[b]furan-2-carbaldehyde Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
23145-16-6	5-Bromobenzo[b]furan-2-carbaldehyde	97+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 23145-16-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 129 - 130 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H5BrO2
Molecular Weight: 225.04

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, strong bases, amines.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 23145-16-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Bromobenzo[b]furan-2-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 23145-16-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 23145-16-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 23145-16-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-1-苯并呋喃-2-甲醛 在 氰化钠 、 sodium methylate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 2-<2-<4-(5-Cyan-1-benzofuran-2-yl)phenyl>-(E)-vinyl>-1-benzofuran-5-carbonitril
  参考文献：
  名称：

  Dann, Otto; Char, Helmut; Griessmeier, Helmut, Liebigs Annalen der Chemie, 1982, # 10, p. 1836 - 1869

  摘要：

  DOI：
• 作为产物：
  描述：

  5-溴苯并呋喃-2-羧酸甲酯 在 甲醇 、 锂硼氢 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 5-溴-1-苯并呋喃-2-甲醛
  参考文献：
  名称：

  [EN] PD-1/PD-L1 INHIBITORS
  [FR] INHIBITEURS PD-1/PD-L1

  摘要：

  根据公式（I）制备的化合物，以及使用这些化合物单独或与其他药剂结合的方法，以及用于治疗癌症的这些化合物的组合物被披露。

  公开号：

  WO2018195321A1

文献信息

• Highly efficient synthesis of aryl and heteroaryl trifluoromethyl ketones via o-iodobenzoic acid (IBX)
  作者：Huicheng Cheng、Yu Pei、Faqiang Leng、Jingya Li、Apeng Liang、Dapeng Zou、Yangjie Wu、Yusheng Wu

  DOI：10.1016/j.tetlet.2013.06.045

  日期：2013.8

  A two-step process for the synthesis of aryl and heteroaryl trifluoromethyl ketones from the corresponding aldehydes is described. Trifluoromethyl alcohols were prepared from aryl and heteroaryl aldehydes in excellent yields using catalytic amount of K2CO3. The trifluoromethyl alcohols were then oxidized conveniently and efficiently by o-iodoxybenzoic acid (IBX) under mild conditions to get the desired

  描述了由相应的醛合成芳基和杂芳基三氟甲基酮的两步法。使用催化量的K 2 CO 3由芳基和杂芳基醛以极好的收率制备三氟甲醇。然后在温和的条件下，通过邻碘氧苯甲酸（IBX）方便有效地氧化三氟甲醇，得到所需的官能化芳基和杂芳基三氟甲基酮。
• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2015042397A1

  公开（公告）日：2015-03-26

  Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

  本文描述了一种I式化合物，制备这种化合物的方法，含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与葡萄糖酰胺合成酶（GCS）相关的疾病或症状的方法。
• [EN] PROTEIN KINASE C AGONISTS<br/>[FR] AGONISTES DE PROTÉINE KINASE C
  申请人：GILEAD SCIENCES INC

  公开号：WO2020176505A1

  公开（公告）日：2020-09-03

  The present disclosure relates generally to certain diacylglycerol lactone compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by protein kinase C (PKC) agonists, such as HIV.

  本公开涉及某些二酰基甘油内酯化合物，包括该化合物的药物组合物，以及制备和使用该化合物和药物组合物的方法。本文所披露的化合物和组合物可用于治疗或预防可通过蛋白激酶C（PKC）激动剂调节的疾病、疾病或感染，如艾滋病。
• Novel inhibitors of Plasmodium falciparum based on 2,5-disubstituted furans
  作者：Susann H. Krake、Pablo David G. Martinez、Jenna McLaren、Eileen Ryan、Gong Chen、Karen White、Susan A. Charman、Simon Campbell、Paul Willis、Luiz Carlos Dias

  DOI：10.1016/j.ejmech.2016.12.024

  日期：2017.1

  mice, although the compound later showed poor metabolic stability in liver microsomes through ring- and side chain-oxidation and N-dealkylation. We describe here the synthesis of derivatives of 1, exploring the influence of substitution patterns around the aromatic ring, variations on the alkyl chain and modifications in the core heterocycle, in order to probe potency and metabolic stability, where 4k

  具有血液疟疾测定法的表型HTS运动已被用于发现与现有药物相比具有潜在替代作用机制的新型疟疾治疗化学型。N 1-（5-（3-氯-4-氟苯基）呋喃-2-基）-N 3，N 3-二甲基丙烷-1,3-二胺1被确定为恶性疟原虫NF54（IC 50  = 875 nM），高剂量口服给小鼠后，血浆半衰期很长，尽管该化合物后来在肝微粒体中通过环和侧链氧化和N代谢表现出较差的代谢稳定性-脱烷基。我们在这里描述1的衍生物的合成，探索芳香环周围的取代方式，烷基链上的变异以及核心杂环中的修饰的影响，以探究效能和代谢稳定性，其中4k显示长的半衰期在大鼠中。
• Cytotoxicity of new pyridazin-3(2<i>H</i>)-one derivatives orchestrating oxidative stress in human triple-negative breast cancer (MDA-MB-468)
  作者：Najat Bouchmaa、Reda Ben Mrid、Youness Boukharsa、Mohamed Nhiri、Hassan Ait Mouse、Jamal Taoufik、M'hammed Ansar、Abdelmajid Zyad

  DOI：10.1002/ardp.201800128

  日期：2018.12

  characterized by high morbidity and mortality. In the absence of targeted therapy, only chemotherapy is available in this case of cancer. The current study investigated the antitumor effect of new pyridazin‐3(2H)‐one derivatives on the human TNBC cell line, MD‐MB‐468. The in vitro cytotoxic activities were investigated using the tetrazolium‐based MTT assay. Lipid peroxidation, H2O2 content, and the specific activities

  三阴性乳腺癌（TNBC）是一种复杂且侵袭性强的乳腺癌亚型，其特点是发病率和死亡率都很高。在没有靶向治疗的情况下，对于这种癌症，只有化疗可用。目前的研究调查了新型哒嗪-3(2H)-one 衍生物对人 TNBC 细胞系 MD-MB-468 的抗肿瘤作用。使用基于四唑的 MTT 测定研究了体外细胞毒活性。还测定了脂质过氧化、H2O2 含量和抗氧化酶的比活性。发现两种分子 6f 和 7h 对肿瘤细胞具有选择性高活性，IC50 值分别为 3.12 和 4.9 µM。此外，暴露于 6f 的细胞显示出 H2O2 和脂质过氧化水平的显着增加，伴随着谷胱甘肽还原酶 (GR) 和硫氧还蛋白还原酶 (TrxR) 的酶活性降低。化合物6f的细胞毒性可以通过抑制GR和TrxR活性来提高目前治疗TNBC的疗效。